Press releases

20 February, 2015

Regulatory

NeuroVive completes a directed share issue of SEK 65 million for continued expansion

NeuroVive Pharmaceutical AB (publ) (”NeuroVive” or the “Company”, OMX:NVP) today announces that the Company has completed a directed share issue of 1.3 million new shares, whic ...

31 March, 2014

Regulatory

NeuroVive Pharmaceutical AB—amendment number of shares and votes

Pursuant to chapter 4, § 9 of the Swedish Financial Instruments Trading Act (1991:980), the company is hereby reporting that as a result of new share issues conducted by NeuroVive Pharmaceutical AB (p ...

13 March, 2014

Regulatory

NeuroVive Pharmaceutical AB—amendment number of shares and votes

As a result of new share issues conducted by NeuroVive Pharmaceutical AB (publ) ("NeuroVive"), as resolved by an Extraordinary General Meeting (EGM) on 13 December 2013, and decided by the Board of Di ...

31 January, 2014

Regulatory

NeuroVive rights issue 270% oversubscribed

NeuroVive Pharmaceutical AB (publ) has completed the rights issue approved by an Extraordinary General Meeting on 13 December 2013. The subscription period was 13-27 January 2014. The rights issue was ...

15 January, 2014

Regulatory

Senior managers’ and Directors’ subscriptions in new issue

Many Directors and senior managers intend to participate in NeuroVive's current rights issue.

18 December, 2013

Regulatory

NeuroVive—SEK 35 m private placement complete, more information on forthcoming SEK 75.8 m rights issue

The private placement reported to the market on 20 November 2013 and approved by the Extraordinary General Meeting (EGM) on 13 December 2013 is now complete.

21 November, 2013

Regulatory

Correction: NeuroVive proposes resolution on private placement and rights issue totaling approximately SEK 111 m

The news release of 20 November at 5:55 p.m. stated the subscription period for the Rights Issue as 13-27 January 2013. The correct dates should be 13-27 January 2014.

20 November, 2013

Regulatory

NeuroVive proposes resolution on private placement and rights issue totaling approximately SEK 111 m

On 20 November 2013, the Board of Directors of NeuroVive Pharmaceutical AB (publ), (the "Company") decided to convene an Extraordinary General Meeting (EGM) and to propose that the Meeting approves a ...